Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
CNY 11.06
(0.36%)
CNY 11.06
(0.36%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.32 Billion CNY | 78.93% |
| 2022 | 744.77 Million CNY | -45.49% |
| 2021 | 1.36 Billion CNY | -28.61% |
| 2020 | 1.91 Billion CNY | -3.46% |
| 2019 | 1.98 Billion CNY | -0.63% |
| 2018 | 1.99 Billion CNY | 11.76% |
| 2017 | 1.78 Billion CNY | 15.69% |
| 2016 | 1.54 Billion CNY | -4.68% |
| 2015 | 1.61 Billion CNY | 61.13% |
| 2014 | 1 Billion CNY | 6.45% |
| 2013 | 943.79 Million CNY | 16.3% |
| 2012 | 811.49 Million CNY | 34.98% |
| 2011 | 601.2 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 656.02 Million CNY | 549.94% |
| 2024 Q2 | 284.81 Million CNY | -56.58% |
| 2024 Q3 | 102.82 Million CNY | -59.96% |
| 2023 Q1 | 679.41 Million CNY | 472.48% |
| 2023 Q4 | 100.93 Million CNY | -76.24% |
| 2023 Q3 | 424.9 Million CNY | 233.56% |
| 2023 Q2 | 127.38 Million CNY | -81.25% |
| 2023 FY | 1.33 Billion CNY | 78.93% |
| 2022 Q4 | -182.4 Million CNY | -227.88% |
| 2022 Q2 | 383.38 Million CNY | -4.43% |
| 2022 Q3 | 142.63 Million CNY | -62.8% |
| 2022 FY | 744.77 Million CNY | -45.49% |
| 2022 Q1 | 401.15 Million CNY | 53.87% |
| 2021 Q1 | 397.2 Million CNY | -50.78% |
| 2021 Q3 | 282.63 Million CNY | -33.63% |
| 2021 Q4 | 260.71 Million CNY | -7.76% |
| 2021 FY | 1.36 Billion CNY | -28.61% |
| 2021 Q2 | 425.84 Million CNY | 7.21% |
| 2020 Q2 | 532.62 Million CNY | 25.79% |
| 2020 Q4 | 806.95 Million CNY | 434.52% |
| 2020 Q1 | 423.43 Million CNY | -22.95% |
| 2020 Q3 | 150.96 Million CNY | -71.66% |
| 2020 FY | 1.91 Billion CNY | -3.46% |
| 2019 FY | 1.98 Billion CNY | -0.63% |
| 2019 Q1 | 572.8 Million CNY | 6.18% |
| 2019 Q2 | 435.25 Million CNY | -24.01% |
| 2019 Q4 | 549.55 Million CNY | 29.31% |
| 2019 Q3 | 424.99 Million CNY | -2.36% |
| 2018 FY | 1.99 Billion CNY | 11.76% |
| 2018 Q4 | 539.44 Million CNY | 7.94% |
| 2018 Q3 | 499.78 Million CNY | -1.82% |
| 2018 Q2 | 509.05 Million CNY | 13.92% |
| 2018 Q1 | 446.84 Million CNY | -30.18% |
| 2017 Q1 | 325.84 Million CNY | -46.23% |
| 2017 FY | 1.78 Billion CNY | 15.69% |
| 2017 Q4 | 640.03 Million CNY | 43.13% |
| 2017 Q3 | 447.18 Million CNY | 20.17% |
| 2017 Q2 | 372.12 Million CNY | 14.2% |
| 2016 FY | 1.54 Billion CNY | -4.68% |
| 2016 Q4 | 606.05 Million CNY | 61.3% |
| 2016 Q3 | 375.72 Million CNY | 12.02% |
| 2016 Q2 | 335.39 Million CNY | 48.48% |
| 2016 Q1 | 225.88 Million CNY | -65.65% |
| 2015 Q1 | 131.3 Million CNY | -68.31% |
| 2015 Q2 | 430.33 Million CNY | 227.75% |
| 2015 FY | 1.61 Billion CNY | 61.13% |
| 2015 Q4 | 657.52 Million CNY | 64.48% |
| 2015 Q3 | 399.74 Million CNY | -7.11% |
| 2014 Q3 | 127.96 Million CNY | -66.17% |
| 2014 FY | 1 Billion CNY | 6.45% |
| 2014 Q4 | 414.36 Million CNY | 223.82% |
| 2014 Q2 | 378.22 Million CNY | 349.46% |
| 2014 Q1 | 84.15 Million CNY | 0.0% |
| 2013 FY | 943.79 Million CNY | 16.3% |
| 2012 FY | 811.49 Million CNY | 34.98% |
| 2011 FY | 601.2 Million CNY | 0.0% |